Jason (Hai) Jiang

Founded in 2012, GeneMind Biosciences is a biotech company located in Shenzhen, China. We are dedicated to developing cutting-edge genome sequencing technologies and tools that can be widely used for every persons healthcare. We believe that genome sequencing is one of the most powerful technologies of the 21st century. By sequencing the millions of individuals, the big data of personal DNA information can bring us closer to curing diseases like cancer and rare genetic diseases, and we can collectively change the world for the better.

Biotheus (普米斯生物技术) aims to discover and develop effective therapeutic biologics for patients with cancer and inflammatory disease. We believe in creative scientific and industrial/academic collaborations in order to reach this common goal.

VISION ABOVE AND BEYOND Immvira was founded in May of 2015 by Prof. Bernard Roizman of University of Chicago and Prof. Grace Zhou formerly a Research Associate Professor at University of Chicago, Prof. Thomas Shenk of Princeton University, Prof. Richard Whitley of University of Alabama, Prof. Ralph Weichselbaum of University of Chicago. Our mission is to develop a broad range of anti-cancer therapies based on genetically engineered viruses and augmented by cancer specific immune factors or chemotherapeutic agents that can be delivered intratumorally or systemically. Our lead candidate, a oHSV encoding IL12 and anti-PD-1Ab (T3) is designed to be administered by direct injection into the tumor mass. In murine tests it is more potent and would be expected to lack the toxicity associated with the systemic administration of immunomodulators alone. Product line 1 already entered clinical trials in January of 2019.

At United Imaging Healthcare, we develop and produce advanced medical products, digital healthcare solutions, and intelligent solutions that cover the entire process of imaging diagnosis and treatment. Founded in 2011, our company has subsidiaries and R&D centers across China, the United States, Poland, Dubai, and other parts of the world. With a cutting-edge digital portfolio and a mission of Equal Healthcare for All™, we help drive industry progress and bold change.

Akeso (HKEX: 09926) is a commercial-stage biopharmaceutical company committed to discovering, developing, manufacturing, and commercializing innovative medicines that address global medical needs. Since our inception, we have established a distinctive and integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the fundamental components, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode.   Akeso is actively developing a diverse pipeline of over 50 innovative assets in cancer, autoimmune disease, inflammation, metabolic disease, and other therapeutic fields. Among these, 19 assets have entered the clinical stage, with 3 innovative drugs already approved, and 13 pivotal/phase III trials ongoing. Utilizing its proprietary Tetrabody technology, Akeso has successfully developed the first-in-class PD-1/CTLA-4 bispecific antibody drug for the market. Additionally, the company has five other innovative bispecific antibody drugs in the clinical stage, including ivonescimab (PD-1/VEGF), PD-1/LAG-3, TIGIT/TGF-Beta, PD-1/CD73, and claudin18.2/CD47 bispecific antibodies.

Founded in 2012, GeneMind Biosciences is a biotech company located in Shenzhen, China. We are dedicated to developing cutting-edge genome sequencing technologies and tools that can be widely used for every persons healthcare. We believe that genome sequencing is one of the most powerful technologies of the 21st century. By sequencing the millions of individuals, the big data of personal DNA information can bring us closer to curing diseases like cancer and rare genetic diseases, and we can collectively change the world for the better.

Biotheus (普米斯生物技术) aims to discover and develop effective therapeutic biologics for patients with cancer and inflammatory disease. We believe in creative scientific and industrial/academic collaborations in order to reach this common goal.

Shenzhen Anke High-tech Co., Ltd.(Anke) is a Sino-US joint venture incorporated by Chinese Academy of Sciences and Analogic Corporation (U.S.A company listed in Nasdaq) in 1986. As the pioneer of Chinese MRI, Anke released Chinas First MRI and produce a series medical imaging devices, such as MRI System, CT Scanner, Digital Radiography System and Mammography System, Ultrasound etc.

VISION ABOVE AND BEYOND Immvira was founded in May of 2015 by Prof. Bernard Roizman of University of Chicago and Prof. Grace Zhou formerly a Research Associate Professor at University of Chicago, Prof. Thomas Shenk of Princeton University, Prof. Richard Whitley of University of Alabama, Prof. Ralph Weichselbaum of University of Chicago. Our mission is to develop a broad range of anti-cancer therapies based on genetically engineered viruses and augmented by cancer specific immune factors or chemotherapeutic agents that can be delivered intratumorally or systemically. Our lead candidate, a oHSV encoding IL12 and anti-PD-1Ab (T3) is designed to be administered by direct injection into the tumor mass. In murine tests it is more potent and would be expected to lack the toxicity associated with the systemic administration of immunomodulators alone. Product line 1 already entered clinical trials in January of 2019.

At United Imaging Healthcare, we develop and produce advanced medical products, digital healthcare solutions, and intelligent solutions that cover the entire process of imaging diagnosis and treatment. Founded in 2011, our company has subsidiaries and R&D centers across China, the United States, Poland, Dubai, and other parts of the world. With a cutting-edge digital portfolio and a mission of Equal Healthcare for All™, we help drive industry progress and bold change.